Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-8186. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB known ✓ | P42338 | 20/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 12/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 12/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 12/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 1.00 |
| ▸ | TOP2B | Q02880 | 1/20 | 1.00 |
| ▸ | ERN2 | Q76MJ5 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-8186 SCHEMBL1638875 | 1.00 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| Azd-8186 SCHEMBL1638635 | 1.00 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1639623 | 0.95 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1638278 | 0.94 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL12668363 | 0.94 | PIK3CB (0.89) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1637208 | 0.94 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1638117 | 0.94 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1638125 | 0.93 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1638867 | 0.92 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL1638272 | 0.92 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | claimed |
| WO-2026090557-A1 | SYSTEMS AND METHODS FOR PROCESSING ISM AND MCAS CLINICAL TRIAL DATA | TELIOS PHARMA INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| WO-2025264581-A1 | P110 INHIBITORS FOR THE TREATMENT OF CANCER | LEAPFROG BIO, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| WO-2025217056-A2 | VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) RECEPTOR ANTAGONISTS FC FUSIONS AND METHODS OF USE | CAMBIUM ONCOLOGY (US) | 2025-10-16 | — | — | WO | claimed |
| EP-4629995-A1 | COMBINATION THERAPY FOR THE TREATMENT OF GLYOBLASTOMA | The University of Florida Research Foundation, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| CN-120152718-A | Combination therapy with substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds | 百时美施贵宝公司 | 2025-06-13 | — | — | CN | claimed |
| WO-2022047008-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2022-03-03 | — | — | WO | claimed |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-10 | — | — | US | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20200390889-A1 | REMOTELY TRIGGERED THERAPY | BAMBU VAULT LLC (US) | 2020-12-17 | — | — | US | claimed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | claimed |
| US-9029374-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2015-05-12 | — | — | US | claimed |
| EP-2493870-B1 | CHROMENONE DERIVATIVES WITH ANTI -TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2014-12-17 | — | — | EP | claimed |
| US-8673906-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2014-03-18 | — | — | US | claimed |
| US-20130158026-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA INTELLECTUAL PROPERTY (GB) | 2013-06-20 | — | — | US | claimed |
| US-8399460-B2 | Chromenone derivatives | ASTRAZENECA AB (GB) | 2013-03-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390889-A1 | REMOTELY TRIGGERED THERAPY | CD47, IFNG, TLR9 | PIK3CB 2755/4885PIK3CD 3463/4885PIK3CA 2448/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | PIK3CB 276/4885PIK3CD 202/4885PIK3CA 52/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | PIK3CB 99/4885PIK3CD 18/4885PIK3CA 13/4885 |
| US-20220040324-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR | WEE1, ERBB3, ERBB2 | PIK3CB 230/4885PIK3CD 206/4885PIK3CA 132/4885 |
| US-20130158026-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | PIK3CB 3920/4885PIK3CD 3037/4885PIK3CA 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.